Overview

The Halting the Epidemic of Addiction and Loss Act of 2025 aims to expand access to opioid overdose reversal drugs by broadening the language used in certain Department of Health and Human Services (HHS) grant programs. The bill seeks to ensure that references to opioid overdose reversal drugs are inclusive of all FDA-approved options, not just naloxone. This change is intended to provide greater flexibility in addressing the opioid crisis and potentially save more lives by allowing grant recipients to utilize the full range of available overdose reversal medications.

Core Provisions

The bill's core provision requires the Secretary of HHS to ensure that any reference to opioid overdose reversal drugs in regulations or guidance for relevant grant programs is inclusive of all FDA-approved options for emergency treatment of known or suspected opioid overdose. Specifically, the Secretary must update existing references in the State and Tribal Opioid Response Grants program and the Priority substance use disorder prevention grants program within one year of the bill's enactment. This change affects how opioid overdose reversal drugs are referenced and potentially used under these grant programs, expanding beyond the current focus on naloxone.

Key Points

• Mandates inclusive language for all FDA-approved opioid overdose reversal drugs in HHS grant programs
• Requires updates to specific grant programs within one year of enactment
• Expands the scope of overdose reversal drugs that can be referenced and used under affected programs

Legal References

• 21st Century Cures Act (42 U.S.C. 290ee–3a)
• Public Health Service Act (42 U.S.C. 290bb–22)
• Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355)

Implementation

The Department of Health and Human Services is responsible for implementing the bill's provisions. The Secretary of HHS must ensure that all relevant regulations and guidance documents are updated to include inclusive language regarding opioid overdose reversal drugs. This includes identifying affected grant programs and modifying their documentation within the one-year timeframe specified in the bill. The implementation does not appear to require new funding mechanisms or establish new reporting requirements, as it primarily involves updating existing language in grant program materials.

Impact

The direct beneficiaries of this bill are grant recipients under the specified HHS programs related to opioid misuse and use disorders. By broadening the language to include all FDA-approved opioid overdose reversal drugs, the bill allows these recipients more flexibility in choosing and using these medications. This could potentially lead to more effective responses to opioid overdoses and save more lives. The administrative burden on HHS is likely to be moderate, as it requires a comprehensive review and update of existing documentation within a year. While no specific cost estimates are provided, the financial impact is expected to be minimal since the bill primarily involves language changes rather than new program creation or funding.

Legal Framework

The bill operates within the existing statutory framework of HHS grant programs, specifically amending language related to the State and Tribal Opioid Response Grants and Priority substance use disorder prevention grants. It relies on the authority of the Secretary of HHS to modify regulations and guidance for these programs. The bill does not appear to preempt state or local laws, nor does it establish new judicial review provisions. Its primary legal effect is to broaden the interpretation and application of existing grant program rules regarding opioid overdose reversal drugs.

Critical Issues

The main implementation challenge for this bill is the one-year timeline for HHS to identify and update all relevant regulations and guidance documents. This could be a significant undertaking depending on the number of affected programs and the complexity of the documentation. There may also be potential resistance from stakeholders who are accustomed to using naloxone specifically, as the broader language could introduce unfamiliarity with newer overdose reversal drugs. Additionally, while the bill aims to increase flexibility, it may inadvertently create confusion if different grant recipients choose to use different overdose reversal drugs, potentially complicating training and standardization efforts across programs.